Sexual and fertility adverse effects associated with chemotherapy treatment in women

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
   PubMed Web of Science ®Google Scholar
• Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 2012;104:386-405
   PubMed Web of Science ®Google Scholar
• Rodriguez-Wallberg KA, Oktay K. Fertility preservation medicine: options for young adults and children with cancer. J Pediatr Hematol Oncol 2010;32:390-6
   PubMed Web of Science ®Google Scholar
• Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004;10:251-66
   PubMed Web of Science ®Google Scholar
• Morgan S, Anderson RA, Gourley C, et al. How do chemotherapeutic agents damage the ovary? Hum Reprod Update 2012;18:525-35
   PubMed Web of Science ®Google Scholar
• Partridge AH, Gelber S, Gelber R, et al. Delayed premature menopause following chemotherapy for early stage breast cancer: long term results from IBSCG Trial V. Proc Am Soc Clin Oncol 2005;16s:687a
   Google Scholar
• Rose DP, Davis TE. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet 1977;1:1174-6
   PubMed Web of Science ®Google Scholar
• González C, Boada M, Devesa M, Veiga A. Concise review: fertility preservation: an update. Stem Cells Transl Med 2012;1:668-72
   PubMed Web of Science ®Google Scholar
• Oktay K, Sönmezer M. Chemotherapy and amenorrhea: risks and treatment options. Curr Opin Obstet Gynecol 2008;20:408-15
   PubMed Web of Science ®Google Scholar
• Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007;110:2222-9
   PubMed Web of Science ®Google Scholar
• Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res 2007;67:10159-62
   PubMed Web of Science ®Google Scholar
• Byrne J, Fears TR, Gail MH, et al. Early menopause in long term survivors of cancer during adolescence. Am J Obstet Gynecol 1992;166:788-93
   PubMed Web of Science ®Google Scholar
• Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-29
   PubMed Web of Science ®Google Scholar
• Salama M, Winkler K, Murach KF, et al. Female fertility loss and preservation: threats and opportunities. Ann Oncol 2013;24:598-608
   PubMed Web of Science ®Google Scholar
• Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-31
   PubMed Web of Science ®Google Scholar
• Swain SM, Land SR, Sundry R, et al. Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C)-docetaxol (T) arm of NSABP-30: preliminary results. Proc Am Soc Clin Oncol 2005;16s:537a
   Google Scholar
• Fornier MN, Modi S, Panageas KS, et al. Incidence of chemotherapyinduced long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005;104:1575-9
   PubMed Web of Science ®Google Scholar
• Soleimani R, Heytens E, Darzynkiewicz Z, Oktay K. Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. Aging 2011;3:782-93
   PubMedGoogle Scholar
• Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res 2007;67:10159-62
   PubMed Web of Science ®Google Scholar
• Titus S, Li F, Stobezki R, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med 2013;5:172ra21
   PubMed Web of Science ®Google Scholar
• Kwee J, Schats R, McDonnell J, et al. Evaluation of anti-Mullerian hormone as a test for the prediction of ovarian reserve. Fertil Steril 2008;90:737-43
   PubMed Web of Science ®Google Scholar
• van Beek RD, van den Heuvel-Eibrink MM, Laven JS. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab 2007;92:3869-74
   PubMed Web of Science ®Google Scholar
• Giuseppe L, Attilio G, Edoardo DN, et al. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology (Am Soc Hematol Educ Program) 2007;12:141-7
   Google Scholar
• Bedoschi G, Oktay K. Current approach to fertility preservation by embryo cryopreservation. Fertil Steril 2013;99:1496-502
   PubMed Web of Science ®Google Scholar
• Practice Committees of American Society for Reproductive Medicine; Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril 2013;99:37-43
   PubMed Web of Science ®Google Scholar
• Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35
   PubMed Web of Science ®Google Scholar
• Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008;26:2630-5
   PubMed Web of Science ®Google Scholar
• Turan V, Bedoschi G, Moy F, Oktay K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. 2013;100:1681-5
   Google Scholar
• Oktay K, Buyuk E, Rodriguez-Wallberg KA, Sahin G. In vitro maturation improves oocytes or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. Reprod Biomed Online 2010;20:634-8
   PubMed Web of Science ®Google Scholar
• Demirtas E, Elizur SE, Holzer H, et al. Immature oocytes retrieval in the luteal phase to preserve fertility in cancer patients. Reprod Biomed Online 2008;17:520-3
   PubMed Web of Science ®Google Scholar
• Chian RC, Uzelac PS, Nargund G. In vitro maturation of human immature oocytes for fertility preservation. Fertil Steril 2013;99:1173-81
   PubMed Web of Science ®Google Scholar
• Stern CJ, Gook D, Hale LG, et al. First reported clinical pregnancy following heterotopic grafting of cryopreserved ovarian tissue in a woman after a bilateral oophorectomy. Hum Reprod 2013;28:2996-9
   PubMed Web of Science ®Google Scholar
• Greve T, Schmidt KT, Kristensen SG, et al. Evaluation of the ovarian reserve in women transplanted with frozen and thawed ovarian cortical tissue. Fertil Steril 2012;97:1394-8
   PubMed Web of Science ®Google Scholar
• Dolmans MM, Marinescu C, Saussoy P, et al. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood 2010;116:2908-14
   PubMed Web of Science ®Google Scholar
• Sánchez-Serrano M, Novella-Maestre E, Roselló-Sastre E, et al. Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation. Hum Reprod 2009;24:2238-43
   PubMed Web of Science ®Google Scholar
• Rosendahl M, Greve T, Andersen CY. The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature. J Assist Reprod Genet 2013;30:11-24
   PubMed Web of Science ®Google Scholar
• Rodriguez-Wallberg KA, Oktay K. Fertility preservation during cancer treatment: clinical guidelines. Cancer Manag Res 2014;6:105-17
   PubMed Web of Science ®Google Scholar
• Bedoschi G, Turan V, Oktay K. Utility of GnRH-agonists for fertility preservation in women with operable breast cancer: is it protective? Curr Breast Cancer Rep 2013;5:302-8
   PubMedGoogle Scholar
• Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2500-10
   PubMed Web of Science ®Google Scholar
• Hancke K, Strauch O, Kissel C, et al. Sphingosine 1-phosphate protects ovaries from chemotherapy-induced damage in vivo. Fertil Steril 2007;87:172-7
   PubMed Web of Science ®Google Scholar
• Paris F, Perez GI, Fuks Z, et al. Sphingosine 1-phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring. Nat Med 2002;8:901-2
   PubMed Web of Science ®Google Scholar
• Bonnaud S, Niaudet C, Pottier G, et al. Sphingosine-1-phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damage-induced mitotic death. Cancer Res 2007;67:1803-11
   PubMed Web of Science ®Google Scholar
• Soleimani R, Heytens E, Oktay K. Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants. PLoS One 2011;6:e19475
   PubMed Web of Science ®Google Scholar
• Li F, Turan V, Lierman S, et al. Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death. Hum Reprod 2014;29:107-13
   PubMed Web of Science ®Google Scholar
• Buster JE. Managing female sexual dysfunction. Fertil Steril 2013;100:905-15
   PubMed Web of Science ®Google Scholar
• Basson R. Female sexual dysfunction in hypopituitarism. Lancet 2007;370:737
   PubMed Web of Science ®Google Scholar
• Falk SJ, Dizon DS. Sexual dysfunction in women with cancer. Fertil Steril 2013;100:916-21
   PubMed Web of Science ®Google Scholar
• Maiorino MI, Bellastella G, Esposito K. Diabetes and sexual dysfunction: current perspectives. Diabetes Metab Syndr Obes 2014;7:95-105
   PubMedGoogle Scholar
• Kennedy SH, Rizvi S. Sexual dysfunction, depression and the impact of antidepressants. J Clin Psychopharmacol 2009;29:157-64
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. American Psychiatric Association, Washington, DC; 2013
   Google Scholar
• Cavalheiro JA, Bittelbrunn A, Menke CH, et al. Sexual function and chemotherapy in postmenopausal women with breast cancer. BMC Womens Health 2012;12:28
   PubMed Web of Science ®Google Scholar
• Gershenson DM, Miller AM, Champion VL, et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:2792-7
   PubMed Web of Science ®Google Scholar
• Spencer SM, Lehman JM, Wynings C, et al. Concerns about breast cancer and relations to psychosocial well-being in a multiethnic sample of early stage patients. Health Psychol 1999;18:159-68
   PubMed Web of Science ®Google Scholar
• Ganz PA, Rowland JH, Desmond K, et al. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501-14
   PubMed Web of Science ®Google Scholar
• Eeltink CM, Incrocci L, Witte BI, et al. Fertility and sexual function in female Hodgkin lymphoma survivors of reproductive age. J Clin Nurs 2013;22(23-24):3513-21
   PubMed Web of Science ®Google Scholar
• Sbitti Y, Kadiri H, Essaidi I, et al. Breast cancer treatment and sexual dysfunction: moroccan women's perception. BMC Womens Health 2011;11:29
   PubMed Web of Science ®Google Scholar
• Akkuzu G, Ayhan A. Sexual functions of Turkish women with gynecologic cancer during the chemotherapy process. Asian Pac J Cancer Prev 2013;14:3561-4
   PubMed Web of Science ®Google Scholar
• Knobf MT. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist 2006;11:96-110
   PubMed Web of Science ®Google Scholar
• Kaplan HS. A neglected issue: the sexual side effects of current treatments for breast cancer. J Sex Martial Ther 1992;18:3-19
   PubMed Web of Science ®Google Scholar
• Schag CA, Ganz PA, Polinsky ML, et al. Characteristics of women at risk for psychosocial distress in the year after breast cancer. J Clin Oncol 1993;11:783-93
   PubMed Web of Science ®Google Scholar
• Breen SJ, Baravelli CM, Schofield PE, et al. Is symptom burden a predictor of anxiety and depression in patients with cancer about to commence chemotherapy? Med J Aust 2009;190:99-104
   PubMed Web of Science ®Google Scholar
• van der Stege JG, Groen H, van Zadelhoff SJ, et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 2008;15:23-31
   PubMed Web of Science ®Google Scholar
• Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 2003;45:29-38
   PubMed Web of Science ®Google Scholar
• Young-McCaughan S. Sexual functioning in women with breast cancer after treatment with adjuvant therapy. Cancer Nurs 1996;19:308-19
   PubMed Web of Science ®Google Scholar
• Dorval M, Maunsell E, Deschenes L, et al. Long-term quality of life after breast cancer: comparison of 8-year survivors with population controls. J Clin Oncol 1998;16:487-94
   PubMed Web of Science ®Google Scholar
• Ganz PA, Desmond KA, Leedham B, et al. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002;94:39-49
   PubMed Web of Science ®Google Scholar
• Leining MG, Gelber S, Rosenberg R, et al. Menopausal-type symptoms in young breast cancer survivors. Ann Oncol 2006;17:1777-82
   PubMed Web of Science ®Google Scholar
• Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol 2008;26:753-8
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:355-69
   PubMed Web of Science ®Google Scholar
• Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259-63
   PubMed Web of Science ®Google Scholar
• Nachtigall LE. Comparative study: replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-80
   PubMed Web of Science ®Google Scholar
• Millheiser LS, Helmer AE, Quintero RB, et al. Is infertility a risk factor for female sexual dysfunction? A case control study. Fertil Steril 2010;94:2022-5
   PubMed Web of Science ®Google Scholar
• Akyuz A, Guvenc G, Ustunsoz A, et al. Living with gynecologic cancer: experience of women and their partner. J Nur Scholarship 2008;40:241-7
   PubMed Web of Science ®Google Scholar
• Pieterse OD, Maas CP, ter Kuile MM, et al. An observational longitudinal study to evaluate miction, defecation, and sexual function after radical hysterectomy with pelvic lymphadenectomy for early-stage cervical cancer. Int J Gynecol Cancer 2006;16:1119-29
   PubMed Web of Science ®Google Scholar